A study describing the in vitro and in vivo evaluation of COTI-2 has been published this month in Oncotarget, a weekly peer-reviewed open access medical journal covering research on all aspects of oncology. The study highlights that COTI-2 is effective against a diverse group of human cancer cell lines regardless of their tissue of origin or genetic makeup. As discussed in the article below, when compared to traditional standard of care therapies, COTI-2 showed comparable to improved single agent activity against tumor cells, in vitro and in vivo.
Welcome to our blog. We use this space to provide more insight into the latest developments in our business as well as recent events in the field of drug discovery and development.